Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Why is the Pharma Industry Buzzing About Real-World Evidence?
Posted on July 30th, 2019 by Xuanyan Xu in Pharma R&D
You have almost certainly heard the terms Real-World Data (RWD) and Real-World Evidence (RWE) – but are you still unsure about exactly what these things are and why they’re important? Let’s break it down.
Real-World Data (RWD) is healthcare information that comes from outside the clinical research setting. It includes data like:
- Electronic health records (lab results, treatment plans, radiology images, etc.)
- Disease and product registries (e.g., Alzheimer’s Prevention Registry, GenomeConnect, Rare Disease Registry Program)
- Claims and billing data (for example, data from health insurance companies that includes information about procedures and demographic information)
- Data from “wearables” and health monitoring devices (e.g., heart rate tracking from an Apple Watch or Fitbit)
Real-World Evidence (RWE) comes from analyzing the above-mentioned types of data. In short, real-world evidence = real-world data + analytics.
What is Driving the Interest in Real-World Evidence?
Here are a few major factors contributing to the pharmaceutical industry’s excitement about RWE:
1) Because regulators take RWE into account, it has the potential to impact approvals and accelerate the drug development process, which could save drug makers a lot of money at a time when cutting costs is critical. One such example comes from Amgen Science, which had a cancer therapy that won its first regulatory approval due to a single-armed Phase 2 study supported by RWE.
2) Real-world evidence complements clinical trials data by providing insights that trials can’t – for instance, safety and effectiveness data from a patient’s daily life. “Sometimes surprising findings can emerge when the narrow constraints of clinical trial eligibility and intent-to-treat analyses are set aside,” explains Nancy A. Dreyer in Stat News. “That’s why it’s time for biotech and pharmaceutical companies to pay more attention to understanding, and undertaking, real-world studies.”
3) It is important to insurance companies and other stakeholders that they have a solid understanding of what benefits a drug offers to patients, and RWE can help bolster their confidence in a treatment’s effectiveness. “Insurance companies, particularly in the U.S., are looking for medicines that can demonstrate improved patient outcomes and reduce hospitalization rates and length of stays,” notes Ed Miseta of Clinical Leader.
Coming Up Next
In an upcoming series of posts on this blog, we will discuss real-world evidence in more depth, covering its impact in the industry, the regulators’ perspective (e.g. EMA, FDA), pharma’s perspective and more
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Sr. Marketing Manager, Life Sciences Audience at Elsevier
- What excites you the most about the Life Sciences industry in 2020?
- The Beneficial Impacts of Real-World Evidence in Drug Development
- FDA Announces Plans to Improve Approvals Process for Medical Devices
- Extreme Makeover: Clinical Trials Edition
- Snakes (aka Chutes) and Ladders – failures and opportunities